Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON–Recurrent Fracture Trial
- 20 January 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Osteoporosis International
- Vol. 22 (9), 2539-2549
- https://doi.org/10.1007/s00198-010-1514-9
Abstract
This study evaluated the benefits of ZOL versus placebo on health-related quality of life (HRQoL) among patients from HORIZON–RFT. At month 24 and end of the study visit, ZOL significantly improved patients’ overall health state compared to placebo as assessed by the EQ-5D VAS. To evaluate the benefits of zoledronic acid (ZOL) versus placebo on health-related quality of life (HRQoL) among patients from The Health Outcomes and Reduced Incidence With Zoledronic Acid Once Yearly Recurrent Fracture Trial (HORIZON–RFT). In this randomized, double-blind, placebo-controlled trial, 2,127 patients were randomized to receive annual infusion of ZOL 5 mg (n = 1,065) or placebo (n = 1,062) within 90 days after surgical repair of low-trauma hip fracture. HRQoL was measured using EQ-5D Visual Analogue Scale (VAS) and utility scores (EuroQol instrument) at months 6, 12, 24, 36, and end of the study visit. Analysis of covariance model included baseline EQ-5D value, region, and treatment as explanatory variables. At baseline, patients (mean age 75 years; 24% men and 76% women) were well matched between treatment groups with mean EQ-5D VAS of 65.82 in ZOL and 65.70 in placebo group. At the end of the study, mean change from baseline in EQ-5D VAS was greater for ZOL vs. placebo in all patients (7.67 ± 0.56 vs. 5.42 ± 0.56), and in subgroups of patients experiencing clinical vertebral fractures (8.86 ± 4.91 vs. −1.69 ± 3.42), non-vertebral fractures (5.03 ± 2.48 vs. −1.07 ± 2.16), and clinical fractures (5.19 ± 2.25 vs. −0.72 ± 1.82) with treatment difference significantly in favor of ZOL. EQ-5D utility scores were comparable for ZOL and placebo groups, but more patients on placebo consistently had extreme difficulty in mobility (1.74% for ZOL vs. 2.13% for placebo; p = 0.6238), self-care (4.92% vs. 6.69%; p = 0.1013), and usual activities (10.28% vs. 12.91%; p = 0.0775). ZOL significantly improves HRQoL in patients with low-trauma hip fracture.Keywords
This publication has 29 references indexed in Scilit:
- Validation of the IOF quality of life questionnaire for patients with wrist fractureOsteoporosis International, 2009
- Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosisOsteoporosis International, 2009
- Zoledronic Acid and Clinical Fractures and Mortality after Hip FractureThe New England Journal of Medicine, 2007
- Determinants of health-related quality of life in women with vertebral fracturesOsteoporosis International, 2005
- Association of low general health status, measured prospectively by Euroqol EQ5D, with osteoporosis, independent of a history of prior fractureOsteoporosis International, 2004
- The HORIZON Recurrent Fracture Trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repairCurrent Medical Research and Opinion, 2004
- Severe Hypocalcemia after Intravenous Bisphosphonate Therapy in Occult Vitamin D DeficiencyThe New England Journal of Medicine, 2003
- Epidemiology and outcomes of osteoporotic fracturesThe Lancet, 2002
- Health-Related Quality of Life in Postmenopausal Women With Low BMD With or Without Prevalent Vertebral FracturesJournal of Bone and Mineral Research, 2000
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990